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a b s t r a c t
The measles virus (MV) vaccine lineage is a promising oncolytic but prior exposure to the measles
vaccine or wild-type MV strains limits treatment utility due to the presence of anti-measles antibodies.
MV entry can be redirected by displaying a polypeptide ligand on the Hemagglutinin (H) C-terminus. We
hypothesized that retargeted MV would escape neutralization by monoclonal antibodies (mAbs)
recognizing the H receptor-binding surface and be less susceptible to neutralization by human antisera.
Using chimeric H proteins, with and without mutations that ablate MV receptor binding, we show that
retargeted MVs escape mAbs that target the H receptor-binding surface by virtue of mutations that ablate
infection via SLAM and CD46. However, C-terminally displayed domains do not mediate virus entry in
the presence of human antibodies that bind to the underlying H domain. In conclusion, utility of
retargeted oncolytic measles viruses does not extend to evasion of human serum neutralization.
& 2014 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/3.0/).
Introduction
Oncolytic virotherapy is an emerging treatment modality for
cancer, which exploits viruses that preferentially infect and kill
cancer cells. These oncolytic viruses include naturally occurring
viruses and viruses that have been engineered for tumor selectivity
(Eager and Nemunaitis, 2011; Donnelly et al., 2012; Russell et al.,
2012). Oncolytic measles virus (MV) vaccine strains, in particular a
laboratory adapted strain of Edmonston vaccine lineage (MV-Edm),
has demonstrated therapeutic potential against different solid
tumors and hematologic malignancies such as hepatocellular carci-
noma (Blechacz et al., 2006), breast cancer (McDonald et al., 2006;
Iankov et al., 2010), prostate cancer (Msaouel et al., 2009a, 2009b),
ovarian cancer (Peng et al., 2002; Hasegawa et al., 2006), multiple
myeloma (Peng et al., 2001; Dingli et al., 2004), lymphoma (Grote
et al., 2001) and glioblastoma multiforme (Phuong et al., 2003) in
preclinical studies. MV-Edm is also being tested clinically for the
treatment of multiple myeloma (NCT00450814), ovarian cancer
(Galanis et al., 2010; NCT00408590), glioblastoma multiforme
(US-0770) and mesothelioma (NCT01503177).
MV is an enveloped, negative-strand RNA virus of the family
Paramyxoviridae (Grifﬁn, 2007). MV-Edm has a tropism for three
cellular receptors: the signaling lymphocyte activating molecule
(SLAM), expressed on activated T and B cells and macrophages
(Tatsuo et al., 2000; Hahm et al., 2003; Schneider-Schaulies et al.,
2002a, 2002b); Nectin-4, a cellular adhesion molecule expressed
in the placenta, trachea, oral mucosa, nasopharynx, and lungs
(Reymond et al., 2001; Noyce et al., 2011) and over-expressed on
several types of cancer (Derycke et al., 2010; Takano et al., 2009;
Fabre-Lafay et al., 2005) and CD46 which is a cellular receptor for
laboratory-adapted MV strains (Naniche et al., 1993). CD46 is a
regulator of complement activation (Naniche et al., 1993; Dorig
et al., 1993) that is ubiquitously expressed on all human nucleated
cells and over-expressed on many different cancer cell types
making them highly susceptible to MV-Edm infection and its
cytopathic effects (Anderson et al., 2004).
MV-Edm can be retargeted to speciﬁc tumor cells by linking
a single-chain antibody (single chain fragment variable, scFv) or
naturally occurring ligand to the virus attachment hemagglutinin
(H) glycoprotein displayed on the virus surface. The ablation of
receptor CD46 and SLAM binding sites limits virus attachment and
entry to cells expressing the receptor for the scFv or ligand linked
to H. Retargeted MV-Edm derivatives retain their oncolytic activity
against xenografts expressing target receptors (Nakamura et al.,
2005; Allen et al., 2006, 2008; Paraskevakou et al., 2007;
Hasegawa et al., 2006; Jing et al., 2009; Hummel et al., 2009;
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Ungerechts et al., 2007; Yaiw et al., 2011). A variety of scFv's have
been displayed on H against different receptors: epidermal growth
factor receptor (EGFR) (Nakamura et al., 2005; Paraskevakou et al.,
2007); EGFRvIII (Nakamura et al., 2005; Allen et al., 2006); HER2/
neu (HER2: Human Epidermal Growth Factor Receptor 2)
(Hasegawa et al., 2007), CD20 (Ungerechts et al., 2007; Yaiw
et al., 2011); folate receptor alpha (Hasegawa et al., 2006); CD38
(Nakamura et al., 2005); carcinoembryonic antigen (CEA)
(Ungerechts et al., 2007), prostate-speciﬁc membrane antigen
(PSMA) (Liu et al., 2009) and an unidentiﬁed receptor over-
expressed on multiple myeloma cells that can be targeted by
Wue scFv (Hummel et al., 2009). Ligands linked to H have also
successfully redirected entry, for example: amino-terminal frag-
ment of urokinase plasminogen activator (uPA) targeting uPA
receptor on breast tumors and tumor stroma (Jing et al., 2009);
snake venom peptide echistatin, targeting integrins αvβ3 and α5β1
expressed on vascular endothelium (Hallak et al., 2005); single-
chain T-cell receptor (scTCR) targeting a speciﬁc peptide/MHC
complex (Peng et al., 2004) and interleukin-13 targeting gliomas
(Allen et al., 2008).
One of the major hurdles for oncolytic virotherapy is preexist-
ing immunity against the oncolytic virus (Parato et al., 2009;
Willmon et al., 2009). Measles oncolytic virotherapy is limited by
preexisting immunity due to wide-spread global vaccination
against measles (Russell and Peng, 2009). The hemaggluntinin
attachment protein is the major target for neutralizing antibodies
(Bouche et al., 2002) that tend to cluster at the receptor binding
surface targeting a conserved neutralizing antigenic region
(Hashiguchi et al., 2007; Hashiguchi et al., 2011b; Santiago et al.,
2010; Ertl et al., 2003; Tahara et al., 2013a). Retargeted MV
derivatives have two modiﬁcations that could potentially destroy
or shield epitopes within the receptor-binding surface. The ﬁrst
modiﬁcation is a set of two (Y481A and R533A) or four (Y481A,
R533A, S548L and F549S) mutations that ablate infection via CD46
and SLAM (Nakamura et al., 2005). The second modiﬁcation is the
scFv or ligand linked to the H C-terminus used to retarget MV to
speciﬁc receptors. This additional polypeptide domain could shield
one or more antibody epitopes and protect the virus from
neutralization (Kneissl et al., 2012). Should the utility of retargeted
oncolytic MVs extend to evasion of serum neutralization it would
render them superior to MV derivatives currently tested clinically.
In this study we used chimeric H proteins with and without
mutations that ablate MV receptor binding to determine if these
mutations protect MV-Edm from mAbs targeting the mutated
receptor-binding surface. We investigated if the displayed domain
can shield mAb epitope(s) and if the size of the domain deter-
mines how well an epitope is protected. We then addressed the
question if retargeted MV derivatives evade human serum
Fig. 1. Recombinant oncolytic measles viruses used in this study. (A) Schematic representation of MV.eGFP-edm (edmonston vaccine lineage, edm). The gene encoding
enhanced green ﬂuorescent protein (eGFP) is at position 1 followed by genes coding for N: nucleoprotein, P: phosphoprotein, M: matrix, F: fusion protein, H: hemagglutinin
and L: large protein. Retargeted viruses are generated by replacing the H gene (Hedm) in MV-eGFP with retargeted H using pac1/spe1 restriction enzymes. Retargeted H can
be either CD46/SLAM tropic (H) or CD46/SLAM blind due to mutations Y481A, R544A, S548L, and F549S (HAALS). Retargeted H or HAALS has a C-terminal scFv/ligand that can
be exchanged with restriction enzymes sﬁ1 and Not1. A 6-histidine peptide (Hisx6) is attached to the C-terminus of scFv/ligand or HAALS. The Hisx6 acts as a ligand for entry
and propagation in Vero cells engineered to express anti-Hisx6 scFv (Vero-HIS cells). The factor Xa (IEGR) cleavage site allows for the removal of the scFv/ligand/Hisx6 from
H and is used to demonstrate that a blind retargeted MV infects cells via scFv/ligand or Hisx6. (B) The table lists the recombinant viruses used in this study; the mutations in
H; the scFv or ligand displayed on H and its size in amino acids. All viruses encode eGFP. For simplicity MV-eGFP is referred to as MV-Hedm. MV-H82-EGFRscFv has a H
glycoprotein with 16 mutations designed to protect seven epitopes from monoclonal antibodies used in this study and is used as a control.
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neutralization, since entry is no longer dependent on H binding
MV receptors, but is mediated by a separate polypeptide domain
attached to the H C-terminus by a linker. Our data demonstrate
that mutations that ablate CD46 and SLAM binding protect
retargeted MV from mAbs targeting the receptor binding-surface
but not from human serum neutralization. The displayed domain
provided no signiﬁcant additional protection from neutralizing
antibodies tested.
Results
Mutations ablating infections via receptors CD46 and SLAM are in
proximity to mAb epitopes within receptor-binding interface
Retargeted recombinant oncolytic measles virus derivatives
used in this study (Fig. 1) have been characterized previously:
MV-H-EGFR.scFv (MV-H6-HAALS-αEGFR) (Nakamura et al., 2005);
MV-H-Ech (MV-ERV) (Hallak et al., 2005); MV-H-Wue.scFv (MV-
Wue) (Hummel et al., 2009). The control virus MV-Hedm will have
a similar susceptibility to monoclonal anti-H antibodies and anti-
MV antibodies present in human serum as oncolytic MVs tested
clinically (NCT00450814; NCT00408590; US-0770; (NCT01503177;
Galanis et al., 2010) as they differ from one another only by the
transgene they encode. Since retargeted H glycoproteins are of a
higher molecular weight their incorporation into the virons is
conﬁrmed by comparing their size to Hedm by immunoblotting
for H (Fig. 2).
To determine the proximity of mAb epitopes that cluster within
and around the receptor-binding surface to mutations in HAALS
(Y481A, R533A, S5548L and F549S) that ablate CD46/SLAM bind-
ing, we mapped the mutations and mAb epitopes onto the crystal
structure of the H protein head domain (Fig. 3). MV receptors
SLAM (Fig. 3A, yellow), CD46 (Fig. 3B, orange) and Necitn-4 (not
shown) bind to the same side of the H head domain (Hashiguchi
et al., 2011a). The receptor ablating mutations in HAALS (Fig. 3C,
marine blue and green) map onto the CD46/SLAM footprint.
Monoclonal antibody (mAb) epitopes clustering within and
around the receptor-binding interface are mapped in magenta
(Fig. 3C). Residue R533 (green) forms part of the 16DE6 epitope
and the R533A mutation in HAALS. MAb epitopes for I-41, 16DE6,
cl48, I-44, I-29, and 16CD11 have been characterized in previous
papers (Hu et al., 1993; Lech et al., 2013). Epitopes for 20H6 and
BH97 were identiﬁed by selecting MV-Hedm in the presence of
20H6 or BH97 and by rational design (unpublished data). Fig. 3C
shows the close proximity of HAALS mutations to mAbs BH97, 20H6
and I-41 and overlap with 16DE6 epitopes. We hypothesized that
the scFv/ligand domain of retargeted H could shield one or more
mAb epitopes. In order to visualize the relative size of a scFv
domain compared to H we manually place a 250 residue scFv
domain using coordinates from the crystal structure of scFv-
against-IL-1β (Wilkinson et al., 2009). The location of the scFv/
ligand domain relative to H is not known as the last 10 C-terminal
H residues are missing from this structure and the scFv/ligand
domain is separated from H by a 9 residue linker.
Retargeted MVs escape neutralization by mAbs targeting the receptor
binding surface but not surrounding areas
Next we investigated if the HAALS mutations protected MV from
neutralizing mAbs targeting the receptor-binding surface and if a
49 residue echistatin domain (Ech) or larger 245 residue Wue or
EGFR scFv domain protected MV from the mAbs analyzed.
MV derivatives, with and without HAALS mutations and scFv/
ligand domains, were incubated with mAbs or media for 1 h at
37 1C prior to infection of Vero-His cells. Infection was quantiﬁed 2
days later by counting the number of eGFP expressing syncytia per
well (Fig. 4). As a positive control we used MV-H82-EGFR.scFv,
whose H protein is modiﬁed with a C-terminal EGFR.scFv/His x6
domain allowing it to be retargeted to EGFR and HIS scFv
expressed on Vero-His cells. The H protein in MV-H82-EGFR.scFv
is engineered to escape completely or partially mAbs tested in this
study by encoding mAb escape mutations and rationally designed
N-linked glycosylations sites within or adjacent to mAb epitopes.
A glycosylation at these sites would have the potential to cloak the
epitope from antibody recognition (Lech et al., 2013); however we
have not determined if the carbohydrates are shielding the
epitopes or the potential N-linked glycosylation site engineered
into the virus is destroying the epitope. The oncolytic potential of
MV-H82-EGFR.scFv has not been tested.
MV derivatives were challenged with mAbs whose epitopes
were within (BH97, 20H6, I-41, and 16DE6) and outside (cl48, I-29,
I-44, and 16CD11) of the receptor-binding surface. MV derivatives,
encoding HAALS mutations evaded neutralization by mAbs 20H6,
I-41, 16DE6 and BH97. (Fig. 4, asterix), whose epitopes all mapped
in close proximity to HAALS mutations (Fig. 3).
MAbs whose epitopes mapped outside of the receptor-binding
surface neutralized all MVs except for control MV-H82.EGFR.scFv.
In the presence of 16CD11 we saw low levels of infection by MVs
displaying scFv/ligand domains with and without HAALS mutations.
MV-HAALS and MV-Hedm, which do not display a scFv/ligand
domain were consistently neutralized. However, following repeat
experiments the level of infection was inconsistent between
retargeted MVs displaying scFv/ligand, except MV-H82.EGFR.scFv.
We can therefore not conclude that a scFv/ligand domain inter-
feres with 16CD11 binding.
Retargeted MV derivatives are neutralized by human serum despite
their resistance to monoclonal antibodies recognizing the receptor-
binding surface
We then investigated if retargeted MV derivatives are less
susceptible to human serum neutralization. Recombinant MV
derivatives were incubated for 2 h at 37 1C in serial dilutions of
human serum prior to infection. We analyzed pooled serum
collected from 100 to 150 male donors at FDA-licensed com-
mercial donor centers within USA (Fig. 5A) or individual males
diagnosed with malignant neoplasms (Fig. 5B–F). Retargeted MV
derivates did not infect cells at higher human serum concentra-
tions than control MV-Hedm (Fig. 5). The neutralization titer (NT,
dilution of serum that neutralized 100% of the virus) differed up to
2-fold between the viruses, which is within the range of experi-
mental variability.
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Fig. 2. Chimeric H proteins displayed on the measles virus. Western immunoblot-
ting of puriﬁed MV-Hedm and retargeted MVs. The size difference between
different chimeric H proteins is based on the size of their C-terminal scFv/ligand.
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Retargeted H glycoproteins with no mutations in H can trigger cell–
cell fusion in the presence of mAb BH97, 20H6 and I-41 targeting the
receptor-binding surface
MV entry into the cell begins with H tethering to the target
receptor. H binding to its receptors could induce a change in H
head orientation, stalk conformation and/or oligomerization
(Lamb et al., 2006; Yuan et al., 2011). H stalk cross-linking studies
suggest that the fusion signal is transmitted via the central region
of the H stalk to F (Navaratnarajah et al., 2011,2012; Russell and
Luque, 2006), which is subsequently destabilized. F then under-
goes a series of conformational changes to induce membrane–
membrane fusion (Lamb et al., 2006; Russell and Luque 2006).
Cells expressing MV H and F glycoproteins interact with MV
receptors on neighboring cells and in the same manner can fuse
these cells together forming syncytia.
We hypothesized that chimeric H glycoproteins – with no
mutations in H – can still bind to the retargeted receptor via their
C-terminal ligand and trigger fusion in the presence of a mAb
recognizing the SLAM/CD46 receptor-binding surface. To test
this hypothesis we performed a cell–cell fusion assay in which
mAbs were added to Vero cells after they were infected with
MVs and quantiﬁed the degree of fusion inhibition (Fig. 6).
Syncytia size in the presence and absence of mAbs was quantiﬁed
by counting the number of nuclei per syncytium and allocating
a score of þ/‐ (≤ 5 nuclei/cells per syncytium), þ (6‐20 nuclei/
cells per syncytium), þþ (21‐50 nuclei/cells per syncytium),
þþþ(>50 nuclei/cells per syncytium). MAbs BH97, 20H6, and
I-41, which bind to the receptor-binding surface, inhibit syncytia
formation between cells infected with MV-Hedm (Fig. 6i), prob-
ably because they inhibit H binding to CD46 expressed in Vero
cells. mAb 16DE6 does not inhibit fusion of Vero cells as its epitope
is in the SLAM binding interface (R533) (Nakamura et al., 2005;
Hashiguchi et al., 2011b). MAbs BH97, 20H6, and I-41 did not
inhibit fusion between cells infected with retargeted viruses
with no mutations in H to the same degree as cells infected with
Fig. 3. HAALS mutations and mAb epitopes map within and around CD46/SLAM binding surface on the hemagglutinin head domain. The crystal structure of the H dimer head
domain (Hashiguchi et al., 2007) (light gray surface representation) is shownwith its native N-linked glycans N168, N187, N200 and N215 (dark gray), which have been built
manually using complex-type penta-antennary sugars. The receptor-binding surface is shared by receptors (A) SLAM (yellow) (Hashiguchi et al., 2011b) and (B) CD46
(orange) (Santiago et al., 2010). (C) HAALS encodes mutations that disrupt SLAM and CD46 binding: Y481A, R533A, S548L, and F549S (box outline marine blue). Mutations
known to escape monoclonal antibodies (red text) within and around the receptor-binding surface are highlighted in magenta. In green is residue R533, which is mutated in
HAALS and forms part of mAb 16DE6 epitope. A representative crystal structure of a 250 amino acid scFv with a C-terminal 6-His peptide domain (Wilkinson et al., 2009) (blue
cartoon representation) is manually placed alongside H to demonstrate its relative size.
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MV-Hedm (Fig. 6i, iii, and v). Since mAbs BH97, 20H6, and I-41
neutralize these viruses (MV-H.Ech and MV-H.WUE, Fig. 4) they are
probably binding to the SLAM/CD46 receptor-binding interface of H
proteins displayed on the cell surface. This suggests that fusion is
triggered by the H C-terminal ligand binding to the retargeted receptor
and that MV-H.Ech and MV-H.Wue are neutralized by these mAbs by
a mechanism other than the inhibition of receptor attachment. As
expected syncytia formation between cells infected by MV's encoding
HAALS mutations (that escape neutralization by these mAbs) are not
inhibited (Fig. 6ii, iv, vi, and vii).
Discussion
MV is a promising oncolytic in preclinical animal models but
anti-measles antibodies limit treatment efﬁcacy in patients. MV H
glycoproteins are the major target for neutralizing antibodies. The
receptor-binding surface is a major target for neutralizing mono-
clonal antibodies and is a conserved neutralizing antigenic site
(Hashiguchi et al., 2011b; Tahara et al., 2013a; Casasnovas et al.,
1999). Since, retargeted MV derivatives use a separate domain
displayed on H to bind selected receptors and encode mutations
ablating native MV receptor binding, it is hypothesized that
retargeted MV derivatives may be less susceptible to human serum
neutralization. Furthermore, the displayed domain could potentially
contribute to serum resistance by shielding one or more antibody
epitopes. This hypothesis is supported by work performed by
Kneissl et al., 2012, who demonstrated that lentiviral vectors
pseudotyped with retargeted MV H and F glycoproteins were less
susceptible to neutralization by human sera from two selected
donors Kneissl et al., 2012.
We therefore studied the susceptibility of recombinant MV
derivatives expressing chimeric H proteins to mAbs and human
serum. Our major ﬁndings are summarized in Table 1. We demon-
strate that mutations in H (HAALS: Y481A, R533A, S5548L, and F549S)
that inhibit entry via receptors SLAM and CD46, protect MV from
neutralizing mAbs targeting the receptor-binding surface (BH97,
20H6, I-41 and 16DE6), but not surrounding areas. The HAALS
mutations do not completely overlap with known epitopes for
BH97, 20H6 and I-41 and we do not know the position of the
scFv/ligand relative to the H protein because a structure of a
retargeted chimeric H protein has not been solved. However based
on our results we conclude that the HAALS mutations are responsible
for escaping neutralizing mAbs BH97, 20H6, I-41 and 16DE6 for the
following reasons: (i) Epitope for 16DE6 overlaps with the HAALS
mutations R533A. (ii) Only retargeted viruses encoding the HAALS
mutations escape mAbs targeting the receptor binding surface and
these viruses escape neutralization despite the size of the C-terminal
extension (i.e., 6 amino acid His peptide, 49 amino acid echistatin
domain or 245 amino acid scFv domain). For example these mAbs
neutralize MV-H-Wue1/Ech but not MV-HAALS-Wue1/Ech. (iii) N-
linked glycosylations native to H do not provide protection against
mAbs tested because Hedm shares the same native carbohydrate
side chains (N-linked glycosylations) as the retargeted H proteins.
Control MV-H82-EGFR.scFv encodes additional N-linked glycosyla-
tion sites within or adjacent to mAb epitopes, which protect the
virus from being neutralized completely by mAbs tested, but these
modiﬁcations are not present in the MVs being studied.
We cannot conclude that the C-terminal scFv/ligand domain
shields the 16CD11 epitope. It is possible that the 49 and 245 residue
domains provide marginal protection because most of the viruses that
display these domains can infect cells at low levels i.e. MV-H.Ech, MV-
HAALS-Ech, MV-HAALS-EGFR, and viruses that do not have these
domains, MV-Hedm and MV-HAALS-His, are neutralized. However,
we cannot explain why MV-HAALS-Wue1 but not MV-H-Wue1 is
neutralized and why the degree of escape by the other viruses varies
between experiments. Due to the fact that the receptor-binding
surface of the H protein is a hot spot for neutralizing antibodies
(Hashiguchi et al., 2007; Hashiguchi et al., 2011b; Santiago et al., 2010;
Ertl et al., 2003; Tahara et al., 2013a) we were surprised that the HAALS
mutations protected this antigenic site from mAbs but provided no
advantage in escaping neutralization by human sera. We tested
pooled human sera available commercially and sera from ﬁve
individuals diagnosed with malignant neoplasms, as this would be
the patient population for oncolytic virotherapy using retargeted MVs.
To escape neutralization from a polyclonal attack by human
antibodies, multiple epitopes may need to be destroyed/protected
on H. The question is which epitopes and how many should be
protected simultaneously. MV-H82-EGFR, in addition to escaping
mAbs targeting the receptor binding surface, escaped mAbs cl48/I-
44 targeting epitope E3 (Lech et al., 2013), I-29 targeting epitope
E4 (Lech et al., 2013) also known as epitope vi (Tahara et al., 2013b)
and partially escaped 16CD11 targeting epitope II (Tahara et al.,
2013b) (Fig. 4). Out of the human sera tested in Fig. 5, two of the
individuals had a 4-fold lower NT for MV-H82-EGFR.scFv than MV-
Hedm (data not shown). The other three individuals NT was 2–3-
folds lower, which we consider to be within the variability range
between repeat PRNT experiments. Hence the combination of
protecting these epitopes gives this virus a marginal advantage
in sera from selected individuals. It would be interesting to protect
Fig. 4. HAALS mutations protect MV from mAbs targeting the receptor binding
surface but not surrounding areas. Measles viruses were incubated in media (no
mAb) or monoclonal antibodies: BH97, cl48, 20H6, I-29, I-44, 16CD11, I-41 and
16DE6 for 1 h at 37 1C, prior to the addition of Vero-His cells. Two days post
infection the number of eGFP expressing infected foci/well were counted using a
ﬂuorescent microscope and plotted as a percentage of infection in the absence of
mAb. This is a representative experiment that was repeated three times. Each data
point is an average of duplicate wells.
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additional epitopes and study their contribution to human anti-
body evasion.
Most of the mAbs targeting the receptor-binding surface
inhibited cell–cell fusion between MV-Hedm infected cells, prob-
ably because they interfere with CD46 receptor binding. We made
the interesting observation that MV-H-Wue and MV-H-Ech dis-
playing unmutated H proteins can trigger fusion in the presence of
these mAbs (Fig. 6). However infection is still inhibited (Fig. 4).
If we assume that these mAbs are bound to the CD46/SLAM
receptor-binding surface whilst H.scFv/ligand/Hisx6 is attached
to His.scFv displayed on Vero-His cells, then it would be
interesting to understand how these mAbs inhibit infection if
fusion is accomplished in future studies.
Conclusions
To date engineered oncolytic viruses currently tested in clinical
trials have not demonstrated dose-limiting toxicities. However
retargeted MV derivatives could potentially be translated into the
clinic if they are shown to be less susceptible to neutralization by
human anti-measles antibodies or to address any future toxicity
Fig. 5. Retargeted MVs do not escape neutralization by human sera. Control MV-Hedm and retargeted MVs were incubated with decreasing concentrations of heat-
inactivated commercially available pooled human sera (A) or sera from ﬁve individuals (B–F) diagnosed with malignant neoplasms. Plotted is the reciprocal serum dilution at
which there was no infection (NT, neutralization titer).
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concerns associated with higher viral doses or treatment of tumors
with low CD46 expression. Here we demonstrate that retargeted
MV derivatives escape neutralization by mAbs targeting the
receptor-binding surface. However, this gives them no advantage
over non-retargeted MVs, in escaping neutralization by human
serum. We propose that this is because multiple neutralizing
epitopes need to be protected simultaneously.
Materials and methods
Cell culture
Retargeted MVs were propagated and titered on Vero Cells
(African green monkey kidney cells) stably expressing membrane-
anchored single-chain antibody that recognizes a six-histidine
peptide (Vero-His), described previously (Nakamura et al., 2005;
Douglas et al., 1999). Vero-His cells were grown in Dulbecco's
Modiﬁed Eagle's Medium (DMEM) with 5% Fetal Bovine Serum
(FBS). Culture media was supplemented with 1% penicillin and
streptomycin (P/S) and cells were grown at 37 1C in a humidiﬁed
atmosphere of 5% CO2.
Cloning of MV-H82.αEGFR
First, the H mutant (H82) was generated by engineering escape
mutations in the Hemagglutin (H) gene (Accession AB583749)
encoded in the pCG plasmid (pCG-H). Mutations in H82 are as
follows: L284S, E395K, E398G, E535N, H536A, A537T, Y310C, D416N,
S546N, R547A, S550T, F552N, Y553G, P554T, S590N, and G592S.
Mutations were added sequentially by site-directed mutagenesis
using the QuikChanges Lightning Site-Directed Mutagenesis Kit
Fig. 6. Monoclonal antibodies targeting the receptor binding surface inhibit fusion between cells infected with MV-Hedm but not retargeted MVs. Vero-His cells were
infected with control MV-Hedm (i) or retargeted MV derivatives (ii–vii) for 13 h prior to replacing the media with media containing mAbs targeting the receptor binding
surface. Average syncytia size was quantiﬁed by counting the number of nuclei per syncytium and allocating a score (viii) of þ/‐ (≤ 5 nuclei/cells per syncytium), þ (6‐20
nuclei/cells per syncytium), þþ (21‐50 nuclei/cells per syncytium), or þþþ(450 nuclei/cells per syncytium) (table viii). The data is presented as the % of syncytia of the
indicated size per 20 syncytia/well. n – Asterix marks percentage of syncytia that have 450 nuclei/cells per syncytium in the presence of mAbs BH97, 20H6, and I-41
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(Agilent Technologies) as per manufacture's directions. The IEGR-
AAQPA-EGFR.scFv-AAA-RGSHHHHHH C-terminal linker and EGFR.
scFv domain were added to H82 by digesting pCG-H82 and pTN-
H6-Haa-αEGFR (Nakamura et al., 2005) with Pac1 and PvuII-HF
(New England biolabs). The H fragment from pCG-H82 replaced
the H fragment in pTN-H6-Haa-αEGFR to generate pTN-H82-αEGFR.
P(þ)MV-H82.αEGFR was then generated by replacing the H gene in
p(þ)MV-eGFP, with H82.αEGFR by digesting p(þ)MV-eGFP and
pTN-H82-αEGFR with restriction enzymes Pac1 and Spe1 (New
England biolabs).
Plasmids, virus rescue and titration
Plasmids encoding full-length MV recombinant derivatives
used for virus rescue are as follows: p(þ)MV-eGFP (Duprex
et al., 1999), p(þ)MV-H-αWue1, p(þ)MV-HAALS-αWue1, p(þ)MV-
H-echistatin (Hallak et al., 2005), p(þ)MV-HAALS-echistatin, p(þ)
MV-HAALS-αEGFR and p(þ)MV-HAALS (Nakamura et al., 2005).
EGFR.scFv, Wue1.scFv and echistatin were inserted into SﬁI/NotI
sites of pTNH6-H or pTNH6-HAALS. Then, the PacI/SpeI fragment of
all H constructs was inserted into the corresponding sites of p(þ)
MVeEGFP as described in Nakamura et al. (2005). The MV rescue
system used for retargeted MV was described previously in
Nakamura et al. (2005) and Msaouel et al., 2012. Titers were
determined by 50% tissue culture infective dose (TCID50) on Vero-
His cells. MV-eGFP is referred to in the text as MV-Hedm.
Immunoblot analysis
Viruses (1105 PFU) were boiled in SDS loading buffer for 5 min
at 95 1C and separated on a 7.5% Tris–glycine SDS-polyacrylamide gel.
Proteins were blotted to nitrocellulose membrane, immunoblotted
with primary antibody: anti-rabbit anti-MV H protein (1:6000
dilution) (made by K.W. Peng, Mayo Clinic) and secondary antibody:
HRP-conjugated goat anti-rabbit (1:5000 dilution).
MV mAb neutralization assay
Due to limited amounts of monoclonal antibodies (mAbs) the
viruses were assayed in duplicate wells and the experiment was
repeated three times. The neutralizing concentration for each mAb
was ﬁrst determined by titration. Neutralizing concentrations used for
the neutralization assay were 16DE6 (1.5 μl ascites/well), 16CD11
(2 μl ascites/well), I-41 (1 μl ascites/well), I-44 (1.5 μl ascites/well), I-
29 (6 μl ascites/well), BH97 (2.5 μg/well), cl48 (1 μg/well), and 20H6
(50 μl hybridoma supernatant). Each of the mAbs was added to a total
volume of 50 μl Opti-MEM/well. This was mixed with equal volume of
MV-Hedm or retargeted MV derivatives (4000 TCID50/ml – which
would yield about 30 syncytia/well 44 hours post infection in the
absence of mAbs). We aim for 30 syncytia/well because based on
experience more than 40 syncytia/well following MV-Hedm (control)
infection makes it very difﬁcult to count individual infectious foci due
to overlap between expanding syncytia. In the case of mAb 20H6, 50 μl
of hybridoma supernatant was mixed with equal volume of virus.
Infection in the absence of monoclonal antibody (no mAb control),
was determined by mixing the virus with equal volume of Opti-MEM.
The mixture was incubated for 1 h at 37 1C before the addition of
Vero-His cells (10,000 cells/well in 50 μl DMEM 5% FBS). Forty-four
hours post infection the number of eGFP expressing syncytia/well in
the absence and presence of mAbs was counted under a ﬂuorescent
microscope. The average number of infectious foci in the absence of
mAb was equated to 100% and the infection in the presence of mAbs
was presented as a percentage of infection in the absence of mAb.
Cell–Cell fusion assay
MV-eGFP (Hedm) and retargeted MV derivatives were diluted
to 4000 TCID50/ml in Opti-MEM. 50 μl of virus was added per well
in a 96 well format. Vero-His cells in DMEM 5% FBS were then
added to the viruses (10,000 cells/well) and the plates were
incubated at 37 1C. Twelve to thirteen hours post infection, mAbs
(BH97, 20H6, I-41, and 16DE6) were diluted as described above in
the section “MV mAb neutralization assay”. The media with virus
was removed from the cells and 50 μl of the diluted mAbs was
added to the cells followed by 50 μl fresh DMEM 5%. Fourty-four
hours post infection the average syncytia size was quantiﬁed by
counting the number of nuclei per syncytium in 20 syncytia/well
and allocating a score of 7(r5 nuclei/cells per syncytium),
þ(6–20 nuclei/cells per syncytium), þþ(21–50 nuclei/cells per
syncytium), or þþþ(450 nuclei/cells per syncytium) (Fielding
et al., 2000). This was done at a magniﬁcation of 20 using
ﬂuorescence and phase-contrast microscopy. The data is repre-
sented as the percentage of syncytia of a particular size in the
absence (no mAb) of presence of mAbs targeting the receptor-
binding interface.
Structural modeling
Models of the hemagglutinin protein were generated using
crystal structure of measles virus hemagglutinin protein alone
Table 1
Summary of major ﬁndings.
Virus name Mutations ablating
CD46/SLAM receptor binding
Retargeted via
C-terminal peptide
mAbs targeting
RBS inhibit infection
mAbs targeting
RBS inhibit fusion via CD46
Human antibodies
inhibit infection
MV-Hedm No No Yes Yes Yes
MV-HAALS Yes Hisx6 No No Yes
MV-H-Ech No Ech, Hisx6 Yes No Yes
MV-HAALS-Ech Yes Ech, Hisx6 No No Yes
MV-H-Wue.scFv No Wue scFv, Hisx6 Yes No Yes
MV-HAALS Yes Wue scFv, Hisx6 No No Yes
MV-HAALS-EGFR.scFv Yes EGFR scFv, Hisx6 No No Yes
RBS, receptor binding site; scFv, single chain fragment variable; Hisx6, six histidine peptide; Ech, Echistatin; AALS, Y481A, R533A, S548L, F549S; mAbs, monoclonal
antibodies.
Major ﬁndings:
 retargeted MVs with CD46/SLAM binding ablated (HAALS), escape neutralization by mAb targeting the receptor binding surface (RBS) but not human antisera.
 Retargeted MVs with no mutations in H are neutralized by mAbs targeting the RBS. Interestingly, these ligand displaying H proteins can still bind to their retargeted
receptors and trigger fusion in a cell–cell fusion assay in the presence of these mAbs. Whilst, non-retargeted Hedm mediated fusion is inhibited.
 Displayed ligands do not protect MV from mAbs tested
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(PDB 2ZB5) (Hashiguchi et al., 2007), in complex with CD46 (PDB
3INB) (Santiago et al., 2010) or SLAM (3ALZ) (Hashiguchi et al.,
2011b). The N-linked complex-sugar model of MV hemagglutinin
globular head was built manually by using the complex-type
penta-antennary sugars whose coordinates were obtained from
the web site http://www.glycosciences.de (Hashiguchi et al., 2007;
Hashiguchi et al., 2011b). A representative structure of a single
chain antibody fragment of the same size as Wue and EGFR scFv
with a C-terminal six Histidine tag was added manually using
scFv-against-IL-1β coordinates (Wilkinson et al., 2009). Crystal
structures were analyzed and manipulated using Educational-
use-only PyMOL software. (http://pymol.org/educational).
Monoclonal antibodies
Monoclonal antibody BH97 was a kind gift from Dr. Claude
Muller, Laboratoire National de Sante, Luxemburg. Antibodies
16DE6, 16CD11, I-41, I-44, and I-29 (Hu et al., 1993) were gifts
from Erling Norrby and Mariethe Ehnlund, Karolinska Institute,
Sweden. MAb cl48 (Giraudon and Wild, 1981) was gifted by Guy
Griesmann and Mark Federspiel at the Mayo Clinic, USA. Antibody
20H6 (Iankov et al., 2013) was gifted by Ianko Iankov and Eva
Galanis, Mayo Clinic, USA.
Plaque reduction neutralization test
Human serum used for this study was as follows: Heat-
inactivated pooled human serum from 100 to 150 male donors
(human AB serum – sterile ﬁltered, Valley Biomedical, product no.
HS1017, lot no. C80553). Individual serum from ﬁve males diag-
nosed with malignant neoplasms, was provided by the Mayo Clinic
Cancer/Normal Serum Bank (IRB Application #: 13-002217). Serum
was diluted in 2 or 4 fold serial dilutions in Opti-MEM (Gibco,
Invitrogen). 50 μl of each serum dilution was added to wells in a 96
well plate in triplicate. Control wells had 50 μl of Opti-MEM with
no serum. Equal volume of MV recombinant derivatives was mixed
with serum dilutions or Opti-MEM control. A standard dilution of
virus in Opti-MEM was adjusted to yield 30 infectious foci per well
in the absence of serum 44 hours post infection. The virus/serum
mixture was incubated for 2 h at 37 1C before the addition of Vero-
His cells in DMEM, 5% FBS (10,000 cells/well). Plates were
incubated for 44 h at 37 1C and the number of eGFP expressing
foci per well was counted using a ﬂuorescent microscope. The
neutralization titer of 100% (NT) was the reciprocal of the dilution
of human serum where there was no infection.
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